<p>Prime Medicine, Inc.（納斯達克代碼：PRME - 獲取免費報告）在週三的午盤交易中股價上漲了 8.4%。該股最高交易價為 4.52 美元，最後交易價為 4.51 美元。在午盤交易中，共成交 1,555,082 股，較平均交易量 3,151,651 股下降了 51%。該股此前收盤價為 4.16 美元。</p>
<p>獲取 <strong>Prime Medicine</strong> 的提醒：</p>
<h2>分析師設定新的價格目標</h2>
<p>多位股票分析師最近對該股進行了評論。Lifesci Capital 在 12 月 23 日的研究報告中將 Prime Medicine 的股票評級上調至 “強力買入”。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Prime Medicine 股票的 “賣出（d-）” 評級。最後，Wall Street Zen 在 11 月 8 日的研究報告中將 Prime Medicine 的評級從 “持有” 下調至 “賣出”。一位股票研究分析師給予該股 “強力買入” 評級，另一位則對該公司發佈了 “賣出” 評級。根據 MarketBeat 的數據，Prime Medicine 目前的共識評級為 “適度買入”。</p>
<p><strong>查看我們最新的 PRME 股票報告</strong></p>
<h2>Prime Medicine 股票上漲 5.5%</h2>
<p>該公司的 50 日移動平均價格為 3.76 美元。該公司的市值為 7.9244 億美元，市盈率為-3.05，貝塔值為 2.71。</p>
<p>Prime Medicine（納斯達克代碼：PRME - 獲取免費報告）最近於 11 月 7 日公佈了季度財報。該公司報告每股收益（EPS）為（0.32 美元），低於分析師的共識預期（0.28 美元）0.04 美元。該季度的收入為 123 萬美元。Prime Medicine 的淨利潤率為-3,301.64%，股本回報率為-163.51%。</p>
<h2>關於 Prime Medicine</h2>
<p>（獲取免費報告）</p>
<p>我們是一家生物技術公司，致力於提供一種新型的差異化一次性治癒基因療法——Prime Editors，以通過部署我們的 Prime Editing 技術來解決最廣泛的疾病譜系。我們認為這種技術是一種多功能、精確、高效且廣泛的基因編輯技術。與疾病相關的基因突變多種多樣，可能從單個鹼基的錯誤（稱為點突變）到超出單個鹼基的錯誤，例如插入、缺失、重複或其組合。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Prime Medicine</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
<li>如果你在美國銀行賬户中存現金……請立即閲讀</li>
<li>將這些代碼輸入你的普通經紀賬户</li>
<li>這個 AI 機會旨在隨着需求的發展而演變</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
<p>在你考慮投資 Prime Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Prime Medicine 並不在名單上。</p>
<p>雖然 Prime Medicine 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRME

<p>Prime Medicine (NASDAQ:PRME) 的股價上漲了 8.4%，達到 4.51 美元，儘管交易量下降了 51%。分析師們的意見不一，Lifesci Capital 給予其 “強力買入” 評級，而 Weiss Ratings 則維持 “賣出” 評級。該公司報告的季度每股收益為（-0.32 美元），未達到預期，市值為 7.9244 億美元，市盈率為 -3.05。Prime Medicine 專注於使用 Prime Editing 技術進行創新的基因療法。目前，在分析師中，它的共識評級為 “適度買入”，但一些人建議更好的投資選擇</p>

<p>Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s share price traded up 8.4% during mid-day trading on Wednesday . The stock traded as high as $4.52 and last traded at $4.51. 1,555,082 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 3,151,651 shares. The stock had previously closed at $4.16.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.（納斯達克代碼：PRME - 獲取免費報告）在週三的午盤交易中股價上漲了 8.4%。該股最高交易價為 4.52 美元，最後交易價為 4.51 美元。在午盤交易中，共成交 1,555,082 股，較平均交易量 3,151,651 股下降了 51%。該股此前收盤價為 4.16 美元。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Prime Medicine</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of equities analysts have recently commented on the stock. Lifesci Capital raised shares of Prime Medicine to a &#34;strong-buy&#34; rating in a research report on Tuesday, December 23rd. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Prime Medicine in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded Prime Medicine from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Prime Medicine presently has a consensus rating of &#34;Moderate Buy&#34;.</p>
<div class="lb-trans"><p>多位股票分析師最近對該股進行了評論。Lifesci Capital 在 12 月 23 日的研究報告中將 Prime Medicine 的股票評級上調至 “強力買入”。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Prime Medicine 股票的 “賣出（d-）” 評級。最後，Wall Street Zen 在 11 月 8 日的研究報告中將 Prime Medicine 的評級從 “持有” 下調至 “賣出”。一位股票研究分析師給予該股 “強力買入” 評級，另一位則對該公司發佈了 “賣出” 評級。根據 MarketBeat 的數據，Prime Medicine 目前的共識評級為 “適度買入”。</p>
</div><p><strong>View Our Latest Stock Report on PRME</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 PRME 股票報告</strong></p>
</div><h2>Prime Medicine Stock Up 5.5%</h2>
<div class="lb-trans"><h2>Prime Medicine 股票上漲 5.5%</h2>
</div><p>The firm's 50-day moving average price is $3.76. The firm has a market cap of $792.44 million, a PE ratio of -3.05 and a beta of 2.71.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 3.76 美元。該公司的市值為 7.9244 億美元，市盈率為-3.05，貝塔值為 2.71。</p>
</div><p>Prime Medicine (NASDAQ:PRME - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.04). The firm had revenue of $1.23 million during the quarter. Prime Medicine had a negative net margin of 3,301.64% and a negative return on equity of 163.51%.</p>
<div class="lb-trans"><p>Prime Medicine（納斯達克代碼：PRME - 獲取免費報告）最近於 11 月 7 日公佈了季度財報。該公司報告每股收益（EPS）為（0.32 美元），低於分析師的共識預期（0.28 美元）0.04 美元。該季度的收入為 123 萬美元。Prime Medicine 的淨利潤率為-3,301.64%，股本回報率為-163.51%。</p>
</div><h2>About Prime Medicine</h2>
<div class="lb-trans"><h2>關於 Prime Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.</p>
<div class="lb-trans"><p>我們是一家生物技術公司，致力於提供一種新型的差異化一次性治癒基因療法——Prime Editors，以通過部署我們的 Prime Editing 技術來解決最廣泛的疾病譜系。我們認為這種技術是一種多功能、精確、高效且廣泛的基因編輯技術。與疾病相關的基因突變多種多樣，可能從單個鹼基的錯誤（稱為點突變）到超出單個鹼基的錯誤，例如插入、缺失、重複或其組合。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>This AI Opportunity Was Built to Evolve With Demand</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Prime Medicine</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
<li>如果你在美國銀行賬户中存現金……請立即閲讀</li>
<li>將這些代碼輸入你的普通經紀賬户</li>
<li>這個 AI 機會旨在隨着需求的發展而演變</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Prime Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Prime Medicine 並不在名單上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prime Medicine 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Prime Medicine（NASDAQ:PRME）股價上漲 8.4% - 你是否應該買入？